Literature DB >> 8645884

Homing of CD4+CD56+ T lymphocytes into kidney allografts during tubular necrosis or rejection.

A Bachetoni1, P Lionetti, P Cinti, P Alò, E R Molajoni, U Di Tondo, V Barnaba, D Alfani, R Cortesini.   

Abstract

The association between acute rejection, acute tubular necrosis, good function and relative infiltration of CD56 subsets of both CD8+ and CD4+ T cells was examined on 67 samples of graft infiltrating cells (GIC) and corresponding peripheral blood lymphocytes (PBL) obtained from renal allograft recipients. Quantification of cell subset profiles was determined by two-color flow cytometry. While a high proportion of CD4+CD56+ GIC was detected when both renal dysfunction and graft cytopathology (acute tubular necrosis or acute rejection) were present, this cell subset was undetectable in peripheral blood. In contrast the CD8+CD56+ T-cell subset was not discriminatory. The presence of CD4+CD56+ cells among freshly-isolated lymphocytes from renal allografts supports the idea that the local environment is involved in the selection of this subset, thus participating in the amplification of the immune-response. In addition, a homing of this T-cell subset into the transplanted organ may constitute an early sign of graft immunopathology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8645884

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  3 in total

1.  TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder.

Authors:  Margarida Lima; Julia Almeida; Maria Dos Anjos Teixeira; Maria del Carmen Alguero Md; Ana Helena Santos; Ana Balanzategui; Maria Luís Queirós; Paloma Bárcena; Antonio Izarra; Sónia Fonseca; Clara Bueno; Benvindo Justiça; Marcos Gonzalez; Jesús F San Miguel; Alberto Orfao
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

2.  Activated natural killer T cells in mice induce acute kidney injury with hematuria through possibly common mechanisms shared by human CD56+ T cells.

Authors:  Takahiro Uchida; Hiroyuki Nakashima; Seigo Ito; Takuya Ishikiriyama; Masahiro Nakashima; Shuhji Seki; Hiroo Kumagai; Naoki Oshima
Journal:  Am J Physiol Renal Physiol       Date:  2018-07-11

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.